慢性乙型肝炎高胆红素血症的临床治疗分析

Clinical Treatment Analysis of Hyperbilirubinemia in Chronic Hepatitis B

目的探讨慢性乙型肝炎高胆红素血症患者的临床治疗方法及效果。方法整群选取2013年2月—2014年2月该院收治的120例慢性乙型肝炎合并高胆红素血症为研究对象,以随机数字表法分成A、B、C、D4组,所有患者均采用常规治疗、保肝治疗,A组在常规基础上加用腺苷蛋氨酸治疗,B组在常规基础上加用舒肝宁治疗,C组在常规基础上加用苦黄注射液治疗,D组在常规基础上加用门冬氨酸-鸟氨酸治疗,对比四组疗效及实验室检查指标。结果B、C、D3组患者的临床疗效比较差异无统计学意义(P>0.05);而A组患者的治疗总有效率显著高于其余3组患者;4组患者均没有出现显著不良反应;治疗后A组患者的临床症状、体征、肝功能改善显著优于其余三组患者(P<0.05)。结论在针对慢性乙型肝炎高胆红素血症患者的治疗中,常规治疗基础上加用腺苷蛋氨酸的临床效果可靠、安全性高。

Objective To discuss the clinical treatment method and effect of patients with hyperbilirubinemia in chronic hepatitis B. Methods 120 cases of patients with hyperbilirubinemia in chronic hepatitis B admitted and treated from February 2013 to February 2014 were selected as the research object and randomly divided into four groups, all patients were given conventional treatment and liver protection treatment, the group A were treated with ademetionine on the basis of conventional treatment, the group B were treated with shuganning on the basis of conventional treatment, the group C were treated with kuhuang injection on the basis of conventional treatment, the group D were treated with L-ornithine-L-aspartate on the basis of conventional treatment, the curative effect and index of laboratory examination of the four groups were compared. Results The difference in the clinical curative effect between the group A, group B and group C had no statistical significance,（P 0.05）, the total treatment effective rate in the group A was obviously higher than the other three groups, adverse reaction did not occur in the four groups, after treatment, the clinical symptoms, signs and improvement of liver function in the group A were obviously better than those in the other three groups,（P0.05）. Conclusion Ademetionine treatment on the basis of the conventional treatment for patients with hyperbilirubinemia in chronic hepatitis B has a reliable clinical effect and high security.